| Literature DB >> 28928886 |
Xue Xiao1,2,3,4, Yi-Bo Meng1,5, Peng Bai6, Juan Zou7, Ya Zhang3, Tri M Bui Nguyen8, Jian-Guo Xiao2, Xue-Mei Gao1,2,9, Bang-Fen Wen3.
Abstract
Objective: Describe for the first time the clinical, epidemiological features of vulvar cancer in southwest China. Identify risk factors and provide reference for the prevention of vulvar cancer. Method: We retrospectively analyzed 885 patients admitted to the West China Second University Hospital for vulvar diseases between 2006 and 2016. Vulvar cancer patients with previously diagnosed vulvar nonneoplastic epithelial disorders (n=132) were analyzed and compared to those without prior history of vulvar nonneoplastic epithelial disorders (n=219). Comparisons were also made among cancer patients and non-cancer patients with vulvar nonneoplastic epithelial disorders (n=288) and vulvar squamous intraepithelial lesions (n=246). The risk factors leading to vulvar cancer for the patients with vulvar nonneoplastic epithelial disorder were analyzed by univariate analysis. Furthermore, differences of the epidemiological features of vulvar nonneoplastic epithelial disorders, vulvar squamous intraepithelial lesion and vulvar cancer were identified.Entities:
Keywords: Vulvar nonneoplastic epithelial disorder; hazardous factors; non-conditional logistic regression.; precancerous lesion; vulvar cancer; vulvar squamous intraepithelial neoplasia
Year: 2017 PMID: 28928886 PMCID: PMC5604446 DOI: 10.7150/jca.20496
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Classification and proportion of 885 cases of patients with vulvar disease
| Item | Number of Cases (Total 885) | Percentage |
|---|---|---|
| Vulvar nonneoplastic epithelial disorder | 288 | 32.54% |
| Lichen simplex chronicus (called squamous cell hyperplasia previously) | 63 | 7.12% |
| lichen sclerosus | 150 | 16.95% |
| other | 75 | 8.47% |
| vulvar squamous intraepithelial neoplasia | 246 | 27.80% |
| Low-grade squamous intraepithelial lesion, LSIL | 36 | 4.07% |
| High-grade squamous intraepithelial lesion, HSIL | 102 | 11.53% |
| Differentiated-type vulvar intraepithelial neoplasia | 108 | 12.20% |
| Vulvar cancer (Vulvar squamous cell carcinoma) | 351 | 39.66% |
| Ⅰ | 195 | 22.03% |
| Ⅱ | 83 | 9.38% |
| Ⅲ | 42 | 4.75% |
| IV | 31 | 3.50% |
| Type of pathological tissue(nonneoplastic pathology before vulvar cancer) | 132 | 14.92% |
| lichen simplex chronicus | 102 | 11.53% |
| lichen sclerosus | 18 | 2.03% |
| other | 12 | 1.36% |
| Vulvar cancer without nonneoplastic disorder history | 219 | 24.75% |
Analyses of hazardous factors for vulvar cancer
| Hazardous factors | Clinical information | VC from NED (n=132) | NED | Chi-square test | |
|---|---|---|---|---|---|
| Age | 33.939 | <0.001 | |||
| >50 | 84 | 96 | |||
| <50 | 48 | 192 | |||
| HPV infection | 26.606 | <0.001 | |||
| YES | 0 | 51 | |||
| NO | 132 | 237 | |||
| Early first coital age | 61.770 | <0.001 | |||
| YES | 42 | 12 | |||
| NO | 90 | 276 | |||
| Multiple gestations (≥3) | 9.772 | 0.002 | |||
| YES | 48 | 63 | |||
| NO | 84 | 225 | |||
| Smoking | 20.193 | <0.001 | |||
| YES | 36 | 42 | |||
| NO | 96 | 246 | |||
| Underlying diseases | 0.000 | 1.000 | |||
| hypertension | 9 | 21 | |||
| diabetes | 3 | 6 | |||
| Atrophic vagina | 14.073 | <0.001 | |||
| YES | 81 | 120 | |||
| NO | 51 | 168 | |||
| Disease of the uterus | 8.250 | 0.016 | |||
| uterine leiomyoma | 6 | 21 | |||
| cervical carcinoma | 3 | 0 | |||
| CIN | 3 | 3 | |||
| Education level (grade) | 50.293 | <0.001 | |||
| >12 | 0 | 87 | |||
| <12 | 132 | 201 | |||
| Pathological type | 25.313 | <0.001 | |||
| lichen simplex chronicus | 102 | 150 | |||
| lichen sclerosus | 18 | 63 | |||
| other | 12 | 75 | |||
| Location of the mixed tumor | 35.383 | <0.001 | |||
| upper | 78 | 84 | |||
| middle | 30 | 132 | |||
| lower | 24 | 72 |
VC from NED: Vulvar cancer resulted from nonneoplastic epithelial disorder; NED: Vulvar nonneoplastic epithelial disorder.
The epidemiological features of vulvar nonneoplastic epithelial disorder, vulvar squamous intraepithelial lesion and vulvar cancer
| Variables | Vulvar Cancer | VSIL | NED | χ2 | ||
|---|---|---|---|---|---|---|
| VC from NED | VC from HSIL | |||||
| Number | 132 | 219 | 246 | 288 | ||
| Age | 51.9±16 | 50.20±15 | 42.71±15 | 45.90±12 | ||
| Early first coital age | 20±3 | 20±4 | 23±2 | 22±3 | ||
| Pregnant times | 4.27±2.25 | 4.02±3.22 | 2.59±1.23 | 2.87±2.01 | ||
| Gestation times | 3.25±2.07 | 3.09±3.01 | 1.66±1.34 | 1.61±2.21 | ||
| Location of the mixed tumor | ||||||
| Upper | 53.79% (71/132) | 16.89%(37/219) | 13.00%(32/246) | 11.81%(34/288) | 117.665 | <0.001 |
| Middle | 18.94%(25/132) | 33.79%(74/219) | 34.15%(84/246) | 31.94%(92/288) | ||
| Lower | 27.27%(36/132) | 49.32%(108/219) | 50.78%(130/246) | 56.25%(162/288) | ||
| Uterine leiomyoma | 4.55%(6/132) | 6.85(15/219) | 7.32(18/246) | 7.29%(21/288) | 1.276 | 0.735 |
| Atrophic vagina | 61.36%(81/132) | 57.08 (125/219) | 44.72(110/246) | 41.67%(120/288) | 21.768 | <0.001 |
| HPV Positive | 0(0/132) | 70.78(155/219) | 83.74(206/246) | 17.71%(51/288) | 399.648 | <0.001 |
| Operation history of vulva | 26.52(35/132) | 23.74%(52/219) | 4.47%(11/246) | 2.78%(8/288) | 91.488 | <0.001 |
| Malignant history | 2.27%(3/132) | 2.74%(6/219) | 4.47%(11/246) | 1.04%(3/288) | 6.240 | 0.101 |
| Hypertention | 12.12%(16/132) | 12.79%(28/219) | 8.94%((22/246) | 2.08%(6/288) | 23.471 | <0.001 |
| DM | 15.15%(20/132) | 15.98%(35/219) | 4.47%(11/246) | 3.82%(11/288) | 35.708 | <0.001 |
| Obsity | 38.64%(51/132) | 36.99%(81/219) | 36.59%(90/246) | 23.96%(69/288) | 15.573 | <0.001 |
VC from NED: Vulvar cancer resulted from nonneoplastic epithelial disorder; VC from HSIL: Vulvar cancer resulted from High-grade squamous intraepithelial lesion; VSIL: vulva squamous intraepithelial lesion; NED: Vulvar nonneoplastic epithelial disorder.
The epidemiological features of vulvar cancer
| Variables | Vulvar Cancer | χ2 | ||
|---|---|---|---|---|
| VC from NED | VC from HSIL | |||
| Age | 51.9±16 | 50.20±15 | ||
| Early first coital age | 20±3 | 20±4 | ||
| Pregnant times | 4.27±2.25 | 4.02±3.22 | ||
| Gestation times | 3.25±2.07 | 3.09±3.01 | ||
| Location of the mixed tumor | ||||
| Upper | 53.79% (71/132) | 16.89%(37/219) | 52.625 | <0.001 |
| Middle | 18.94%(25/132) | 33.79%(74/219) | ||
| Lower | 27.27%(36/132) | 49.32%(108/219) | ||
| Uterine leiomyoma | 4.55%(6/132) | 6.85(15/219) | 0.777 | 0.378 |
| Atrophic vagina | 61.36%(81/132) | 57.08 (125/219) | 0.624 | 0.430 |
| HPV Positive | 0(0/132) | 70.78(155/219) | 167.306 | <0.001 |
| Operation history of vulvar | 26.52(35/132) | 23.74%(52/219) | 0.339 | 0.560 |
| Malignancy history | 2.27%(3/132) | 2.74(6/219) | 0.072 | 0.789 |
| Hypertension | 12.12%(16/132) | 12.79%(28/219) | 0.033 | 0.856 |
| Diabetes Mellitus | 15.15%(20/132) | 15.98%(35/219) | 0.043 | 0.836 |
| Obesity | 38.64%(51/132) | 36.99%(81/219) | 0.096 | 0.757 |
VC from NED: Vulvar cancer resulted from nonneoplastic epithelial disorder; VC from HSIL: Vulvar cancer resulted from High-grade squamous intraepithelial lesion.
Diagnosis time, recurrence rate and survival rate of vulvar cancer
| Type of pathological tissue | Lichen simplex chronicus | vulvar lichen scleroses | |
|---|---|---|---|
| Diagnosis time before | 10.6 | 6.2 | |
| 3-year survival rate | 79.4% (27/34) | 50% (3/6) | |
| 5 year survival rate | 70.6%(24/34) | 50% (3/6) | |
| Recurrence rate | 44.1% (15/34) | 33.3% (2/6) |